Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.53 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331043 | 1.00 | TYMS (0.55) | TYMSPOLBDNMT1DNMT3B | |
| SCHEMBL28011043 | 0.93 | TYMS (0.49) | TYMSPOLBDNMT1DNMT3B | |
| SCHEMBL14660974 | 0.92 | POLB (0.55) | TYMSPOLBDNMT1DNMT3B | |
| SCHEMBL2926533 | 0.92 | POLB (0.55) | TYMSPOLBDNMT1DNMT3B | |
| SCHEMBL16431293 | 0.92 | POLB (0.54) | TYMSPOLBDNMT1DNMT3B | |
| SCHEMBL15810651 | 0.90 | POLG (0.54) | POLBDNMT1DNMT3B | |
| SCHEMBL20906737 | 0.90 | POLG (0.54) | POLBDNMT1DNMT3B | |
| SCHEMBL22300298 | 0.90 | POLG (0.54) | POLBDNMT1DNMT3B | |
| SCHEMBL336251 | 0.90 | POLG (0.54) | POLBDNMT1DNMT3B | |
| SCHEMBL15201233 | 0.90 | POLG (0.54) | POLBDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097405-B1 | Nucleic acid sequencing processes using non-radioactive detectable modified or labeled nucleotides or nucleotide analogs, and other processes for nucleic acid detection and chromosomal characterization using such non-radioactive detectable modified or labeled nucleotides or nucleotide analogs | ENZO BIOCHEM, INC. (US) | 2012-01-17 | — | — | US | claimed |
| US-6992180-B1 | Oligo- or polynucleotides comprising phosphate-moiety labeled nucleotides | ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-20260125749-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12595509-B2 | Synthetic nucleic acid spike-ins | KARIUS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260072019-A1 | METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12553085-B2 | Sequencing kit | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20260043809-A1 | AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY | UNIV OXFORD INNOVATION LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260028379-A1 | MUTANT PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-01-29 | — | — | US | disclosed |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-12-30 | — | — | US | disclosed |
| EP-4665753-A1 | ARMOURED REGULATORY T CELL | King's College London (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361502-A1 | Promoters And Compositions | UNIV OXFORD INNOVATION LTD (GB) | 2025-11-27 | — | — | US | disclosed |
| EP-0618228-A1 | Protein with a moiety capable of chelating ions attached thereto | ENZO BIOCHEM, INC. (US) | 1994-10-05 | — | — | EP | disclosed |
| US-5260433-A | Nonradioactive | ENZO DIAGNOSTICS, INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5241060-A | Base moiety-labeled detectable nucleatide | ENZO DIAGNOSTICS, INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0302175-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1989-02-08 | — | — | EP | disclosed |
| EP-0286898-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| EP-0285950-A2 | A drug delivery conjugate | ENZO BIOCHEM, INC. (US) | 1988-10-12 | — | — | EP | disclosed |
| EP-0285058-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0097373-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1984-01-04 | — | — | EP | disclosed |
| US-4017606-A | CYTOSINE ARABINOSIDE AND HYDROGENATED PYRIMIDINE NUCLEOSIDES | THE UPJOHN COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072019-A1 | METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE | NUP210, EPCAM, PHAX | TYMS 2007/4885POLB 1826/4885DNMT1 2398/4885 |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | DNA2, MTREX, DDX21 | TYMS 997/4885POLB 48/4885DNMT1 123/4885 |
| US-20260043809-A1 | AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY | DDX6, DDX1, DDB1 | TYMS 2902/4885POLB 647/4885DNMT1 679/4885 |
| US-12553085-B2 | Sequencing kit | PHAX, TIA1, POLM | TYMS 1750/4885POLB 684/4885DNMT1 1190/4885 |
| US-20260125749-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | POLRMT, PITPNB, NUP205 | TYMS 1917/4885POLB 81/4885DNMT1 959/4885 |
| US-20260028379-A1 | MUTANT PORE | PTMS, NUP50, NUP205 | TYMS 3991/4885POLB 2195/4885DNMT1 2912/4885 |
| US-12595509-B2 | Synthetic nucleic acid spike-ins | SPOUT1, NOP2, METTL16 | TYMS 1196/4885POLB 594/4885DNMT1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.